Entelo Bio
About Entelo Bio
Entelo Bio is a Therapeutics startup based in London, United Kingdom that has raised $4M in venture capital across 1 funding round. The company reached Seed stage in April 2026 with a $4M round led by Ananda Impact Ventures. Entelo Bio's investor base includes 2 institutional funds, with Ananda Impact Ventures leading the most recent equity round.
Entelo Bio is an AIxBio company focused on the biology of movement and ageing. Built on pioneering multi-omics and computational biology research from the Botnar Institute for Musculoskeletal Sciences at the University of Oxford, the company has developed proprietary clinical, wet-lab and AI infrastructure to fuel biological discovery and translation for the 1.7 billion people living with conditions that impair movement — from chronic age-associated diseases through to rare genetic disorders. Entelo Bio combines a global clinical community with human-centric disease models to validate AI predictions, decoding disease complexity with unmatched resolution to enable precision medicine in human physical resilience.
Entelo Bio Funding Rounds Timeline
1 rounds · $4M raised
| Round | Date | Amount | Valuation | Lead investor | Co-investors |
|---|---|---|---|---|---|
| Seed | April 2026 | $4M | — | Ananda Impact Ventures | The Creator Fund |
Investors in Entelo Bio
2 institutional investors across 1 rounds
Lead investors
Co-investors
Recent news about Entelo Bio
- FundingEntelo Bio raises $4M to transform human physical resilienceApril 2026
Questions about Entelo Bio
How much has Entelo Bio raised?
Entelo Bio has raised $4M across 1 funding round since null.
Who are the investors of Entelo Bio?
Entelo Bio's investors include Ananda Impact Ventures, The Creator Fund.
When was Entelo Bio's last funding round?
Entelo Bio's most recent round was a $4M Seed in April 2026, led by Ananda Impact Ventures.